Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial

X Xiaohua Wu (Fudan University Shanghai Cancer Center Shanghai China) J Jing Wang (Hunan Cancer Hospital Changsha China) D Danbo Wang (Cancer Hospital of China Medical University Liaoning Cancer Hospital and Institute Shenyang China) G Guiling Li (Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China) J Jieqing Zhang H Hongmin Chen (Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences) H Hongying Yang (Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University Kunming China) Q Qi Zhou (Chongqing University Cancer Hospital Chongqing China) K Ke Wang (Tianjin Medical University Cancer Institute and Hospital Tianjin China) Y Yumei Wu T Tienan Yi J Jihong Liu Y Yi Huang (Hubei Cancer Hospital Wuhan China) Y Yuxian Bai K Keming Wang K Kui Jiang (The Second Affiliated Hospital of Dalian Medical University Dalian China) H Hanmei Lou R Ruifang An (The First Affiliated Hospital of Xi’an Jiaotong University Xi’an China) X Xiumin Li (Linyi Cancer Hospital Linyi China) Y Yueyin Pan Y Yue Wang W Weiping Tao K Kun Song Y Yu Kang (College of Pharmaceutical Sciences) Y Yuzhi Li W Wenyu Shi A Anwen Liu Y Ying Yang Y Yijun Wang (Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University) K Keyan Chen H Haiyan Shi P Puhan Lu P Panfeng Tan S Songhua Fan M Michael Shi W Weiguo Su